/PRNewswire/ The "China Vaccine Market, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has.
The vaccine acts against potentially fatal pneumococcal infections such as pneumonia, septicaemia and meningitis. The doses will be sent to government medical stores depots (GMSD) in Kolkata, Mumbai and Karnal on Wednesday. The SII has to supply 2.4 crore doses of the vaccine to the Health Ministry by December 2021. It will be sent to 37 consignees all over India. The supply order was issued on February 3 in the name of Prakash Kumar Singh, the director of Government and Regulatory Affairs at the Pune-based SII. The Health Ministry s order was placed within two days of Finance Minister Nirmala Sitharaman announcing in her 2021-22 Union Budget speech that indigenously made pneumococcal vaccines will be rolled out across the country.
Clinical trials and use of the vaccine
India s drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate Vaccine (PCV), after reviewing the phase 1, 2, and 3 clinical trial data submitted by the Pune-based firm. This vaccine is used for active immunization against invasive disease and pneumonia caused by
Streptococcus pneumonia in infants, the Health Ministry had said.
SII conducted clinical trials in India and Gambia (Africa).
Statement We have achieved one more historical milestone during the lockdown
In a letter addressed to Vardhan, Prakash Kumar Singh, Additional Director, Government, and Regulatory Affairs at SII said, Moving toward Prime Minister s clarion call of